Standout Papers

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung ... 2013 2026 2017 2021 372
  1. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial (2013)
    Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 75 standout
Sub-graph 1 of 22

Citing Papers

Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Designing antibodies as therapeutics
2022 Standout
2 intermediate papers

Works of Anna Bettini being referenced

Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
2013 Standout

Author Peers

Author Last Decade Papers Cites
Anna Bettini 570 564 201 25 857
Janice F. Eakle 555 340 260 22 788
Eleanor Gutteridge 538 260 194 25 779
Elisabetta Campagnoli 638 433 344 19 932
Peter F. Lenehan 459 413 126 17 817
Astrid Hirschmann 417 359 201 20 854
Philippe Montcuquet 574 328 243 39 905
Axel R. Hanauske 418 480 131 19 1.0k
Luigi Maiorino 867 699 229 47 1.2k
Hidehiko Shimokawa 427 560 152 53 950
Jonas Leichsenring 474 395 344 31 813

All Works

Loading papers...

Rankless by CCL
2026